AuditLine › HHS OIG › Centers for Medicare and Medicaid Services
HHS OIG recommendation 21-E-03-009.03
CMS should collaborate with States to conduct greater oversight of Medicaid MCOs� management of specialty drugs; this oversight could include a…
The recommendation, in the publisher's words
CMS should collaborate with States to conduct greater oversight of Medicaid MCOs� management of specialty drugs; this oversight could include a review of contract language that allows States to obtain requested information on specialty drug categorizations, specialty drug reimbursement methodologies, and cost management strategies.
- Responsible agency
- Centers for Medicare and Medicaid Services
- Issued
- December 23, 2020
- Report
- States Could Do More to Oversee Spending and Contain Medicaid Costs for Specialty Drugs (OEI-03-17-00430) · find it at HHS OIG
- Kind of report
- Evaluation
- Agency response
- Concur (as recorded by the publisher)
- Closed
- November 19, 2024 (publisher's date)
- Publisher topics
- Financial Stewardship, Prescription Drug
“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.
Dated history
- Issued by HHS OIG. (publisher's date)
- Closed, with status “Closed Implemented”. (publisher's date)
- First recorded by AuditLine. (start of AuditLine's own history for this record)
- The publisher changed the recommendation's wording. (observed by AuditLine in the publisher's file)
Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.
Other recommendations from this report
2 more, of which 1 is open in the publisher's file.
- CMS should work with States to expand alternative reimbursement models to address the rising costs for drugs often categorized as specialty drugs.HHS OIG 21-E-03-009.01 · issued Dec 23, 2020 · closed Oct 27, 2022Closed Implemented
- CMS should provide States with acquisition cost data for a wider range of specialty drugs.HHS OIG 21-E-03-009.02 · issued Dec 23, 2020Open Unimplemented
Source
Open this report in HHS OIG's tracker This publisher's records (CSV)
Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows,
SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.